A Novel Compound for Alcoholism Treatment: A Translational Strategy
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2019
Price : $35 *
At a glance
- Drugs PF 5190457 (Primary)
- Indications Alcohol-related disorders
- Focus Adverse reactions
- 10 Jun 2019 Results evaluating the biotransformation of PF-51904577 in vitro and from this study's sample in humans were published in the Drug Metabolism and Disposition.
- 02 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 02 Dec 2014 Planned number of patients changed from 15 to 20 as reported by ClinicalTrials.gov record.